Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation

Taysha Gene Therapies, Inc.

2024-Q1 EPS reported -$0.10 revenue$3,411,000

Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.
FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.
Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.
Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.
Cash $124M; expects to fund operations into 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-138253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.